EY Announces Kevin Hrusovsky, President, Chairman And Chief Executive Officer Of Quanterix And Founder Of Powering Precision Health As An Entrepreneur Of The Year ® 2018 Award Finalist In The New England Region
Lexington, Mass. – Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, President, Chairman and CEO of Quanterix, and Founder of Powering Precision Health (PPH), has been named by EY as a finalist for the Entrepreneur Of The Year® 2018 Award in the New England program. The recognition acknowledges Hrusovsky’s achievements in health care technology innovation, Quanterix’ outstanding financial performance, and his personal commitment to improving precision medicine and human health.
“We are honored to be recognized by EY for this award” said Hrusovsky. “This recognition honors the many people and institutions that are driving a precision health vision to eradicate and prevent some of today’s most lethal diseases, namely cancer, Alzheimer’s and infectious disease. It’s a privilege for us to be recognized alongside other entrepreneurs and business leaders who are all pioneers in their respective fields.”
Hrusovsky has a more than 25 year-long track record commercializing disruptive technologies in the life science industry. His impressive career has been propelled by a unique leadership style marked by transparency, passion, and purpose. Since joining Quanterix less than four years ago, Hrusovsky has transformed the company from one that lacked mission and direction into a successful public entity with industry-leading technology that has the power to transform the way we diagnose and treat disease. The key is his focus on putting science first. With Hrusovsky at the helm, Quanterix now has over 200 peer-reviewed publications backing the abilities of its Simoa technology, a significant industry accomplishment. He’s also expanded the applications for Simoa in the drug development industry, with 18 out of the top 20 pharmaceutical companies having used the technology to date in over 700 clinical trials.
Two years ago, Hrusovsky realized that more needed to be done to drive a true transformation in our healthcare system. As such, he launched PPH as a forum where all key stakeholders, from the world’s leading medical professions and innovators to patients and patient advocates, could come together to share their latest research and truly revolutionize medicine. Now in its third year, PPH has sparked a true movement, one that puts science before profits and closely examines how we can prevent diseases, not just treat them. Today PPH has more than doubled in size and is considered the leading industry conference focused on advancing precision health.
Hrusovsky also serves on the Board of Directors of several companies shaping the future of precision health, including Quanterix, BioreclamationIVT, Cell Signaling Technology, 908 Devices, SynapDx and Solect Energy. He also serves on the Educational Board of the Massachusetts Biotech Council, the Advisory Committee for the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation, the JALA Editorial Board, and the Strategy Committee of Children’s Hospital Boston.
Hrusovsky was selected as a finalist by a panel of independent judges. Award winners will be announced at a special gala event on June 28, 2018 at the Westin Boston Waterfront. Now in its 32nd year, the program has expanded to recognize business leaders in more than 145 cities in more than 60 countries throughout the world.
Regional award winners are eligible for consideration for the Entrepreneur Of The Year National competition. Award winners in several national categories, as well as the Entrepreneur Of The Year National Overall Award winner, will be announced at the Entrepreneur Of The Year National Awards gala in Palm Springs, California, on November 10, 2018. The awards are the culminating event of the Strategic Growth Forum®, the nation’s most prestigious gathering of high-growth, market-leading companies.
Founded and produced by EY, the Entrepreneur Of The Year Awards are nationally sponsored in the US by SAP America, the Kauffman Foundation and Merrill Corporation.
In the New England region, gold sponsors also include Boston Private Bank, fama PR, the Isenberg School of Management at the University of Massachusetts Amherst, Nixon Peabody, True Search, and Woodruff Sawyer. New England silver sponsors include Chatham Financial, Empire Valuation Consultants, Morgan Lewis, Sullivan & Worcester, and T3 Advisors.
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit https://www.quanterix.com.
About Entrepreneur Of The Year®
Entrepreneur Of The Year®, founded by EY, is the world’s most prestigious business awards program for entrepreneurs, chosen from an independent panel of judges including entrepreneurs and prominent leaders from business, finance, and the local community. The program makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global awards program of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities and more than 60 countries. ey.com/eoy
About EY’s Growth Markets Network
EY’s worldwide Growth Markets Network is dedicated to serving the changing needs of high-growth companies. For more than 30 years, we’ve helped many of the world’s most dynamic and ambitious companies grow into market leaders. Whether working with international mid-cap companies or early stage, venture-backed businesses, our professionals draw upon their extensive experience, insight and global resources to help your business succeed. For more information, please visit us at ey.com/sgm or follow news on Twitter @EY_Growth.
EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.
EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to Simoa’s potential ability to change the way in which healthcare is provided today, and are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Share this page